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Duchene Muscular Dystrophy (DMD) is the most common lethal X-linked recessive muscle 
disease, affecting nearly one out of every 3,500 newborn males.  Symptoms appear before age 
three and by eleven, most children are unable to walk.  Few live past the age of 25.The genetic 
disorder is caused by a mutation in the dystrophin gene, eradicating the body’s ability to 
produce the cytoskeletal protein, dystrophin.  In normal muscle cells, dystrophin is part of a 
molecular complex that adds mechanical integrity to the sarcolemma by linking the cytoskeleton 
to the extracellular matrix.  When the complex is disrupted, as in the case of DMD, the 
membrane is easily torn during regular muscle use.  Damage to the membrane causes aberrant 
influxes of Ca++, initiating a cascade of devastating molecular events in the sarcomere.  
Elevated Ca++ over activates a family of proteases known as calpains. Calpains cleave proteins 
at specific sites.  Over-active calpains are thought to contribute to pathology in DMD.  
Compounds that hinder calpain activity present a possible treatment for the disease.  A novel 
protease inhibitor has shown promising results in preliminary investigations in mice and this 
study was proposed to further explore the compound’s effect on gene expression in canine 
muscle. An Affymetrix canine microarray was used to compare mRNA expression between 
normal dogs, dogs with golden retriever muscular dystrophy (GRMD), and inhibitor-treated 
GRMD dogs.  By comparing these expression levels, we are able to speculate whether calpain 
inhibitor treatment is able to mitigate aberrant gene expression in GRMD dogs.  Analysis of raw 
data is ongoing.  Further study is required to determine if mRNA levels equate with the protein 
expression levels using PCR, Western Blotting, or other methods. 
 
 
